Top in endocrinology: Coffee, tea reduce cardiometabolic risk; novel weight loss drug
Click Here to Manage Email Alerts
Drinking caffeinated beverages as an adult may lower the risk for developing multiple cardiometabolic diseases compared with adults who do not consume caffeine, according to study findings.
In an analysis of data from the UK Biobank published in The Journal of Clinical Endocrinology & Metabolism, researchers found that drinking 100 mg caffeine or more per day lowered risk for type 2 diabetes, coronary heart disease and stroke. The most significant risk reduction occurred among adults who consumed 2.6 to 3.5 drinks of coffee per day or 200 mg to 300 mg caffeine daily.
It was the top story in endocrinology last week.
In another top story, individuals with obesity and metabolic syndrome experienced weight loss after receiving monlunabant, a novel small-molecule oral cannabinoid receptor 1 inverse agonist manufactured by Novo Nordisk as a part of a phase 2a study.
Read these and more top stories in endocrinology below:
Drinking moderate amounts of caffeine may cut risk for multiple cardiometabolic diseases
Adults who drink caffeinated beverages such as coffee or tea may have a lower risk for developing multiple cardiometabolic diseases compared with adults with low or no intake, according to study findings. Read more.
Novel oral drug linked to weight loss in people with obesity, metabolic syndrome
Novo Nordisk announced that monlunabant, a novel small-molecule oral cannabinoid receptor 1 inverse agonist, was associated with weight loss in a phase 2a study of people with obesity and metabolic syndrome. Read more.
New oral obesity drug safe, linked to weight loss in first-in-human study
In a first-in-human study, a novel oral amylin and GLP-1 receptor coagonist appeared safe and tolerable and lowered weight compared with placebo at 12 weeks in patients with obesity, researchers reported. Read more.
FDA clears implantable CGM with sensor that lasts up to 1 year
The FDA has cleared a continuous glucose monitoring system with an implantable sensor that can be worn for up to 1 year for adults aged 18 years and older with type 1 or type 2 diabetes, according to a press release. Read more.
Off-label semaglutide, tirzepatide lower HbA1c and body weight in type 1 diabetes
Adults with type 1 diabetes using either semaglutide or tirzepatide off-label had greater decreases in body weight and HbA1c than those not treated with either medication, according to a speaker at the European Association for the Study of Diabetes annual meeting. Read more.